Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025GlobeNewsWire • 11/04/25
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025GlobeNewsWire • 09/26/25
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 CatalystSeeking Alpha • 09/25/25
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to SanofiGlobeNewsWire • 09/25/25
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to SanofiGlobeNewsWire • 09/24/25
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewsWire • 09/24/25
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25GlobeNewsWire • 09/10/25
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with OlomorasibGlobeNewsWire • 08/25/25
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/13/25
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate AtebimetinibGlobeNewsWire • 07/09/25
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer PatientsGlobeNewsWire • 06/17/25
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025GlobeNewsWire • 06/16/25
Immuneering Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/05/25
Immuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/25
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/20/25
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/03/25